Vidac Pharma's CEO will present at the 19th Annual European Life Sciences CEO Forum in Zurich on March 4–5, 2026, covering clinical advancements and pipeline expansion. Lead candidate VDA-1102 has shown efficacy in Phase 2b actinic keratosis and Phase 2A cutaneous T-cell lymphoma.
FDA clears SkinStylus for periorbital wrinkles across all skin types; accepts Biofrontera's sNDA for Ameluz PDT in superficial BCC with a September 2026 PDUFA date; Belite Bio completes rolling NDA submission for tinlarebant in Stargardt disease.
The FDA has cleared an IND for Amphista's novel BRD9 degrader AMX-883 for AML, approved Lantheus' new prostate cancer imaging agent Pylarify TruVu, and accepted Biofrontera's sNDA for Ameluz PDT in superficial basal cell carcinoma. These regulatory milestones span hematologic and solid tumor areas, addressing significant unmet medical needs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07648407 |
Therapeutic Induction of Dermal Remodeling in Veterans to Prevent Actinic Neoplasia Caused by Chronic Environmental Exposure to Ultraviolet Radiation |
NOT_YET_RECRUITING | NA |
| NCT07513454 |
A Phase 2 Study of HW211026 |
NOT_YET_RECRUITING | PHASE2 |
